Premier Alternatives

Vima Therapeutics

Cambridge, MA · Founded 2023 · Privately Held (backing)

Developer of oral therapeutics designed for the treatment of movement disorders. Vima Therapeutics is based in Cambridge, MA and was founded in 2023. Its last reported valuation was $118 million in Mar 2026. It has raised $100 million.

Last reported valuation
$118.0M
Oct 2026
Priced at
—
Total raised
$100.0M
Last round
—

Vima Therapeutics key facts

as of Oct 2026
  • Developer of oral therapeutics designed for the treatment of movement disorders.
  • Vima Therapeutics is valued at approximately $118.0M as of Oct 2026 (last reported valuation).
  • It has raised $100.0M; the latest was Early Stage VC ($100.0M) in Mar 2026.
  • Notable investors include Frazier Healthcare Partners, Atlas Venture, Access Biotechnology, Canaan Creative.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$118.0M

Vima Therapeutics's last reported valuation, Mar 2026. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Private Market View
More of Vima Therapeutics with a free Private Market View account
  • ·Watch Vima Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Vima Therapeutics funding rounds

No rounds on record

No funding rounds for Vima Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Vima Therapeutics valuation

Vima Therapeutics's last reported valuation was $118 million in Mar 2026. No priced round, secondary trade or fund mark has surfaced since.

Vima Therapeutics investors

4 investors are on record for Vima Therapeutics, including Frazier Healthcare Partners, Atlas Venture, Access Biotechnology and Canaan Creative.

About Vima Therapeutics

Developer of oral therapeutics designed for the treatment of movement disorders. The company offers clinical-stage biotechnology research focused on targeting the underlying causes of dystonia through advanced pharmacological approaches, providing patients with improved motor control, enhanced treatment efficacy, and better tolerability while addressing the neurological mechanisms responsible for involuntary muscle contractions.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2023
Employees
20
Ownership
Privately Held (backing)

Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.